Nippon India Pharma Fund Direct Growth is a Equity Mutual Fund Scheme launched by Reliance Mutual Fund. This scheme was introduced to investors on 01 Jan 2013. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Direct Growth.The fund currently has an Asset Under Management(AUM) of ₹2,332 Cr and the Latest NAV as of 22 Oct 2019 is ₹151.89.
The Nippon India Pharma Fund Direct Growth is rated High risk. Minimum SIP Investment is 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 year.
To generate consistent returns by investing in equity or fixed income securities of pharma and other associated companies.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
Scheme Information Document(SID)
Min for First Investment
Min for Second Investment
Exit load of 1% if redeemed within 1 year